Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study
Compose a Response to This Article
Other responses
No responses have been published for this article.
